BC Environmental and Occupational Health Research Network

The Leukemia & Lymphoma Society’s (LLS) Translational Research Program (TRP) was established to encourage and provide support for new and novel clinical research. The goal of the program is to accelerate transfer of findings from the laboratory to clinical application. The program’s purpose is to fund research that shows high promise for translating basic biomedical knowledge to prevention or new treatments and, ultimately, to prolong and enhance life.
Awards will be limited to a maximum of $200,000, which include direct costs and a maximum overhead of $20,000 or 11.1 percent of direct costs per year for three years. Budget requests should be carefully justified and commensurate with the needs of the project.

The Marshall A. Lichtman Specialized Center of Research (SCOR) program was established to encourage multidisciplinary research focused on the prevention, diagnosis, or treatment of leukemia, lymphoma or myeloma. The program requires synergy among at least three research programs and these programs may be supported by scientific core laboratories. The program permits an application for a competitive renewal of the SCOR grant after five years depending on the progress shown. The program is organized to encourage the interaction of complementary sciences and the linkage of basic sciences to a translational research program.

Scholars in Clinical Research are highly qualified investigators who are expected to hold independent faculty-level appointments and who are conducting original, independent applied research, often involving early-stage clinical trials which will advance the prevention, diagnosis or treatment of hematologic malignancies. These Scholars are expected to have concomitant support for their research from another source or agency. Scholar in Clinical Research awards are for $110,000 per year for five years. Annual renewals are based on a non-competitive progress report review.

Scholars in Clinical Research are highly qualified investigators who are expected to hold independent faculty-level appointments and who are conducting original, independent applied research, often involving early-stage clinical trials which will advance the prevention, diagnosis or treatment of hematologic malignancies. These Scholars are expected to have concomitant support for their research from another source or agency. Scholar in Clinical Research awards are for $110,000 per year for five years. Annual renewals are based on a non-competitive progress report review.

Scholars are highly qualified investigators who have shown a capacity for independent, sustained original investigation in the field of leukemia, lymphoma, and myeloma. These Scholars are expected to hold independent faculty-level or equivalent positions and have obtained substantial support for their research from a national agency. Scholar awards are for $110,000 per year for five years. Annual renewals are based on a non-competitive progress report review.